Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neoantigen-Specific Immunotherapy”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Looking for participantsNCT07002203
What this trial is testing

Personalized Neoantigen Peptide Vaccines for Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRecurrent Cancer+2 more
Seqker Biosciences, Inc. 10
Not applicableUnknownNCT05633641
What this trial is testing

Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell Carcinoma
Fudan University 60
Not applicableStudy completedNCT05158621
What this trial is testing

A Screening Study Targeting Tumor-specific Antigens

Who this might be right for
Metastatic Colorectal CancerStage II/III Colon Cancer
Gritstone bio, Inc. 22
Large-scale testing (Phase 3)Active Not RecruitingNCT05141721
What this trial is testing

A Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Who this might be right for
Colorectal Neoplasms
Seattle Project Corporation 700
Very early researchEnrolling By InvitationNCT07316361
What this trial is testing

GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer

Who this might be right for
Endometrial CarcinomaEndometrial Carcinoma Stage III
Biogenea Pharmaceuticals Ltd. 40
Testing effectiveness (Phase 2)Ended earlyNCT05194735
What this trial is testing

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Who this might be right for
Gynecologic CancerColorectal CancerPancreatic Cancer+9 more
Alaunos Therapeutics 8